JNJ vs PEPG

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Score Change Explanation: The previous score of 80/100 (8/10) on 2026-02-13 was based on PepGen's robust EDO platform and lead candidate PGN-EDO51 for DMD, anticipating future market leadership. However, since the last analysis, material adverse events have significantly altered the investment thesis and risk profile. On March 4, 2026, the FDA placed a partial clinical hold on the FREEDOM2-DM1 Pha...